Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
9,21 USD | +0,55% | -1,39% | -17,91% |
Omzet 2024 * | 50 mln. 46,76 mln. | Omzet 2025 * | 71,15 mln. 66,54 mln. | Marktkapitalisatie | 250 mln. 233 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 5 mln. 4,68 mln. | Nettowinst (verlies) 2025 * | 26 mln. 24,32 mln. | EV/omzet 2024 * | 4,99 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 3,51 x |
K/w-verhouding 2024 * |
44,2
x | K/w-verhouding 2025 * |
9,89
x | Werknemers | 29 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 84,71% |
Recentste transcriptie over Fennec Pharmaceuticals Inc.
1 dag | +0,55% | ||
1 week | -1,39% | ||
Lopende maand | -17,18% | ||
1 maand | -15,43% | ||
3 maanden | -6,97% | ||
6 maanden | +32,90% | ||
Lopend jaar | -17,91% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Rostislav Raykov
CEO | Chief Executive Officer | 48 | 07-07-09 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 07-07-09 |
Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chris Rallis
BRD | Director/Board Member | 70 | 25-08-11 |
Khalid Islam
CHM | Chairman | 67 | 25-04-14 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 07-07-09 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.00% | 34 M€ | +2,14% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 9,21 | +0,55% | 154 291 |
25-04-24 | 9,16 | +0,99% | 120 030 |
24-04-24 | 9,07 | -1,84% | 182 107 |
23-04-24 | 9,24 | -1,49% | 288 706 |
22-04-24 | 9,38 | +0,43% | 165 455 |
uitgestelde koers Nasdaq, 26 april 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-17,91% | 250 mln. | |
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |